Publications
Imidazo[1,5-a]quinoxalines as
Irreversible BTK Inhibitors for the Treatment of
Rheumatoid Arthritis. Kyung-Hee Kim, Andreas Maderna,
Mark E. Schnute, Martin Hegen, Shashi Mohan Joy
Miyashiro, Laura Lin, Evelyn Li, Sean Keegan,
Jennifer Lussier, Christopher Wrocklage, Cheryl L.
Nickerson-Nutter, Arthur J. Wittwer, Holly Soutter,
Nicole Caspers, Seungil Han, Ravi Kurumbail, Kyri
Dunussi-Joannopoulos, John Douhan III, and Allan
Wissner. Bioorg. Med. Chem.,
2011, 21,
6258-6263.
The identification of
8,9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c][2,7]naphthyridin-4-ylamines
as potent inhibitors of 3-phosphoinositide-dependent
kinase-1 (PDK-1). Nittoli T, Dushin RG, Ingalls C,
Cheung K, Floyd MB, Fraser H, Olland A, Hu Y, Grosu
G, Han X, Arndt K, Guo B, Wissner A., Eur. J. Med.
Chem. 2010, 45,
1379-86.
Benzo[c][2,7]naphthyridines as
inhibitors of PDK-1. Kyung-Hee Kim, Allan Wissner,
Middleton B. Floyd Jr. , Heidi L. Fraser, Yanong D.
Wang, Russell G. Dushin, Yongbo Hu, Andrea Olland,
Bing Guo, and Kim Arndt Bioorg. Med. Chem. Let.
2009, 19, 5225-5228.
Synthesis and PKCq
inhibitory activity of a series of
4-indolylamino-5-phenyl-3-pyridinecarbonitriles.
Dushin, R.l G.; Nittoli, T.; Ingalls, C.A; Boschelli,
D. H.; Cole, D. C.; Wissner, A.; Lee, J.; Yang, X.;
Morgan, P.l; Brennan, A.; Chaudhary, D Bioorg. Med.
Chem. Let. 2009, 19,
2461-2463.
Kinase Domain Mutations
in Cancer: Implications for Small Molecule Drug
Design Strategies. Bikker, J. A.; Brooijmans, N.;
Wissner, A.; Mansour, T. S. J. Med. Chem.,
2009, 52 1493-1509.
Identification,
Characterization and Initial Hit-to-Lead Optimization
of a Series of 4-Arylamino-3-Pyridinecarbonitrile as
Protein Kinase C theta (PKCθ) Inhibitors D. C. Cole,.
Asselin, A. Brennan, Czerwinski, J.W. Ellingboe, .
Fitz, R. Greco, X.Huang, D.Joseph-McCarthy, M, F.
Kelly, M. Kirisits, J. Lee, Y. Li, P.l Morgan, J. R.
Stock, D. H. H. Tsao, A. Wissner, X.Yang, and D.
Chaudhary, J. Med. Chem., 2008;
51, 5958-5963.
The Development of
HKI-272 and Related Compounds for the Treatment of
Cancer. Allan Wissner and Tarek Mansour, Arch. Pharm.
Chem. Life Sci., 2008, 341,
465-477.
Dual Irreversible
Kinase Inhibitors: Quinazoline-based Inhibitors
Incorporating Two Independent Reactive Centers with
Each Targeting Different Cysteine Residues in the
Kinase Domains of EGFR and VEGFR-2. Allan Wissner,
Heidi L. Fraser, Charles L. Ingalls, Russell G.
Dushin, M. Brawner Floyd, Kinwang Cheung1, Thomas
Nittoli, Malini R. Ravi, Xingzhi Tan, Frank Loganzo.
Bioorg. Med. Chem., 2007,
3635-3648.
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones
as Covalent-Binding, Irreversible Inhibitors of the
Kinase Domain of Vascular Endothelial Growth Factor
Receptor-2 Wissner, A.; Floyd, M. B.; Johnson, B. D.;
Fraser, H.; Ingalls, C.; Nittoli, T.; Dushin, R. G.;
Discafani, C.; Nilakantan, R.; Marini, J.; Ravi, M.;
Cheung, K.; Tan, X.; Musto, S.; Annable, T.; Siegel,
M. M.; Loganzo, F.; J. Med. Chem.,
2005; 48, 7560-7581.
Irreversible inhibitors
of the EGF receptor may circumvent acquired
resistance to gefitinib. Eunice L. Kwak, Raffaella
Sordella, Daphne W. Bell, Nadia Godin-Heymann, Ross
A. Okimoto, Brian W. Brannigan, Patricia L. Harris,
David R. Driscoll, Panos Fidias, Thomas J. Lynch,
Sridhar K. Rabindran, John P. McGinnis, Allan
Wissner, Sreenath V. Sharma, Kurt J. Isselbacher,
Jeffrey Settleman, and Daniel A. Haber Proc. Nat.
Acad. Sci., 2005, 102,
7665-7670.
Optimization of
6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles
as Orally Active, Irreversible Inhibitors of Human
Epidermal Growth Factor Receptor-2 Kinase Activity.
Hwei-Ru Tsou, Elsebe G. Overbeek-Klumpers, William A.
Hallett, Marvin F. Reich, M. Brawner Floyd, Bernard
D. Johnson,Ronald S. Michalak, Ramaswamy Nilakantan,
Carolyn Discafani, Jonathan Golas, Sridhar K.
Rabindran, Ru Shen, Xiaoqing Shi, Yu-Fen Wang Janis
Upeslacis, and Allan Wissner J. Med. Chem.,
2005, 48, 1107 -1131
Antitumor Activity of
HKI-272, an Orally Active, Irreversible Inhibitor of
the HER-2 Tyrosine Kinase. Sridhar K. Rabindran,
Carolyn M. Discafani, Edward C. Rosfjord, Michelle
Baxter, M. Brawner Floyd, Jonathan Golas, William A.
Hallett, Bernard D. Johnson, Ramaswamy Nilakantan,
Elsebe Overbeek, Marvin F. Reich, Ru Shen, Xiaoqing
Shi, Hwei-Ru Tsou, Yu-Fen Wang and Allan Wissner
Cancer Research , 2004, 64,
3958-3965
Syntheses and EGFR
kinase inhibitory activity of 6-substituted-4-anilino
[1,7] and [1,8] naphthyridine-3-carbonitriles. A.
Wissner, P. R. Hamann , R. Nilakantan , L. M.
Greenberger , F. Ye , T. A. Rapuano and F. Loganzo.
Bioorg. Med. Chem. Lett., 2004,
14, 1411-1416
Synthesis and
evaluation of
4-Anilino-6,7-dialkoxy-3-quinolinecarbonitriles as
inhibitors of kinases of the Ras-MAPK signaling
cascade. Dan Berger, Minu Dutia, Dennis Powell, Biqi
Wu, Allan Wissner, Diane H. Boschelli, M. Brawner
Floyd, Nan Zhang, Nancy Torres, Jeremy Levin, Xuemei
Du, Donald Wojciechowicz, Carolyn Discafani,
Constance Kohler, Steven C. Kim, Larry R. Feldberg,
Karen Collins and Robert Mallon. Bioorganic &
Medicinal Chemistry Letters 2003,
13, 3031-3034.
Synthesis and
Structure-Activity Relationships of 6,7-Disubstituted
4-Anilinoquinoline-3-Carbonitriles. The Design of an
Orally Active, Irreversible Inhibitor of the Tyrosine
Kinase Activity of the Epidermal Growth Factor
Receptor (EGFR) and the Human Epidermal Growth Factor
Receptor-2 (HER-2). A. Wissner, E. Overbeek, M. F.
Reich, M. B. Floyd, B. D. Johnson, N. Mamuya, E. C.
Rosfjord. C. Discafani, R. Davis, X. Shi, S. K.
Rabindran, B. C. Gruber, F..Ye, W. A. Hallett,
R.Nilakantan, R. Shen, Y-F. Wang, L. M. Greenberger,
and H.Tsou. J. Med. Chem.,
2003, 46,
49-63.
Syntheses and EGFR and
HER-2 Kinase Inhibitory Activities of
4-Anilinoquinoline-3-Carbonitriles. Analogues of
Three Important 4-Anilinoquinazolines Currently
Undergoing Clinical Evaluation as Therapeutic
Antitumor Agents. A. Wissner, M. B. Floyd, S. K.
Rabindran, R. Nilakantan, L. M. Greenberger, R. Shen,
Y.-F. Wang and H. Tsou. . Bioorg. Med. Chem. Lett.
2002, 12, 2893-2897.
8-Anilinoimidazo[4,5-g]quinoline-7-carbonitriles
as Src Kinase Inhibitors. Dan Berger, Minu Dutia,
Dennis Powell, Biqi Wu, Allan Wissner, Frenel
DeMorin, Jennifer Weber, and Frank Boschelli. Bioorg.
Med. Chem. Lett, 2002, 12,
2761-2765.
Substituted
4-Anilino-7-phenyl-3-quinolinecarbonitriles as Src
Kinase Inhibitors. Dan Berger, Minu Dutia, Dennis
Powell, Allan Wissner, Frenel DeMorin, Yuri Raifeld,
Jennifer Weber, and Frank Boschelli. Bioorg. Med.
Chem. Lett., 2002, 12,
2989-2992.
4-Anilino-3-cyanobenzo[g}quinolines
as Kinase Inhibitors. N. Zhang, B. Wu, A. Wissner,
D.W. Powell, S. K. Rabindran, C. Kohler, and F.
Boschelli. Bioorg. Med. Chem. Lett.,
2002, 12, 423-425.
6-Substituted-4-(3-bromophenylamino)quinazolines
as Putative Irreversible Inhibitors of the Epidermal
Growth Factor Receptor (EGFR) and Human Epidermal
Growth Factor Receptor (HER-2) Tyrosine Kinases with
Enhanced Antitumor Activity. H-R Tsou, N. Mamuya, B.
D. Johnson, M. F. Reich, B. C. Gruber, F. Ye, R.
Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R.
Davis, F. E. Koehn, L. M. Greenberger, Y.-Fen Wang,
and A. Wissner J. Med. Chem. 2001,
44, 2719-2734.
MEK (MAPKK) inhibitors.
Part 2: Structure¯Activity Relationships of
4-Anilino-3-cyano-6,7-dialkoxyquinolines. Nan Zhang,
Biqi Wu, Nancy Eudy, Yanong Wang, Fei Ye, Dennis
Powell, Allan Wissner, Larry R. Feldberg, Steven C.
Kim, Robert Mallon, Eleonora D. Kovacs, Lourdes
Toral-Barza and Constance A. Kohler. Bioorg. Med.
Chem. Lett., 2001, 11,
1407-1410.
Tris(trimethylsilyloxy)ethylene. A.
Wissner. e-EROS Encyclopedia of Reagents for Organic
Synthesis, 2001
Synthesis and Src
Kinase Inhibitory Activity of a Series of
4-Phenylamino-3-quinolinecarbonitriles D. H.
Boschelli, Y. D, Wang, F.Ye, B. Wu, N. Zhang, M.
Dutia, D. W. Powell, A. Wissner, K. Arndt, J. M.
Weber, and F. Boschelli. . J. Med. Chem.
2001, 44, 822-833.
Synthesis and
Structure-Activity Relationships of
3-Cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK)
Inhibitors. N. Zhang, B. Wu, D. Powell, A. Wissner,
M. B. Floyd, E. D. Kovacs, L. Toral-Barza and C.
Kohler. Bioorg. Med. Chem. Lett.,
2000, 10, 4700.
Inhibitors of Src
tyrosine kinase: The Preparation and
Structure-Activity Relationship of
4-Anilino-3-cyanoquinolines and
4-Anilinoquinazolines. Y. D. Wang, K. Miller, D. H.
Boschelli, F. Ye, B. Wu, M. B. Floyd, D. W. Powell,
A. Wissner, J.M. Weber and F. Boschelli. Bioorg. Med.
Chem. Lett., 2000, 10,
2477-2480.
Inhibitors of the
Mek/Erk MAP Kinase Pathway as Anti-Tumor Agents. N.
Zhang, B. Wu, D. Powell, A. Wissner, L. Toral-Barza,
E. D. Kovacs, and C. Kohler. Frontiers of
Biotechnology & Pharmaceuticals, Science Press
New York Ltd., 2000, Vol.
1. 305-313.
Combinatorial
Chemoprevention of Intestinal Neoplasia. C. J.
Torrance, P. E. Jackson. E. Montgomery, A. Wissner,
K. W. Kinzler, B. Vogelstein, P. Frost, C. M.
Discafani. Nature Medicine 2000,
6, 1024-1028.
4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile
Inhibitors of Epidermal Growth Factor Receptor Kinase
and Their Bioisosteric Relationship to the
4-Anilino-6,7-dialkoxyquinazoline Inhibitors. A.
Wissner, D. M. Berger, D. H. Boschelli, M. B. Floyd,
Jr., L. M. Greenberger, B. C. Gruber, B. D. Johnson,
N. Mamuya, R. Nilakantan, M. F. Reich, R. Shen, H.-R.
Tsou, E. Upeslacis, Y. Fen Wang, B. Wu, F. Ye, and N.
Zhang. J. Med. Chem. 2000,
43, 3244-3256.
CL-387,785: an
irreversible inhibitor of epidermal growth factor
receptor tyrosine kinase with in vivo activity. C. M.
Discafani, M. Carroll, M. B. Floyd, Jr., I. J.
Hollander, Z. Husain, B. D. Johnson, D. Kitchen, M.
K. May, A. A. Minnick, Jr. , R. Nilakantan, R. Shen,
Y. Wang, A.. Wissner, L. M. Greenberger Biochem.
Pharm.,1999, 57, 917-925
.
Asymmetric Synthesis of
cis and trans--Lactones Useful in HIV-1 Protease
Inhibitor Synthesis. Michael P. Trova, Allan Wissner,
Wellington T. Casscles, Jr., and Grace C. Hsu.
Bioorg. & Med. Chem. Lett,.1994,
4, 903-906, .
Effect of CL 184,005, A
Platelet-Activating Factor Antagonist in a Murine
Model of Staphylococcus aureus-Induced Gram-Positive
Sepsis. DeJoy, S.Q.; Jeyaseelan, R.; Torley, L.W.;
Pickett, W.C.; Wissner, A.; Wick, M.M.; Oronsky,
A.L.; Kerwar, S.S. J. Infect. Disease,
1994, 169(1),
150-156.
Novel Ortho Effects
Detected in the Fast Atom Bombardment Mass Spectra of
Substituted Bisaryl Phosphate Antagonists of
Platelet-Activating Factor. Siegel, M.M.; Tsao, R.;
Wissner, A. Org Mass Spec.,1993,
28, 1297.
Synthesis and
Biological Evaluation of A Series of HIV-1 Protease
Inhibitors. Michael P. Trova, Robert E. Babine,
Randal A. Byrn, Wellington T. Casscles, Jr., Richard
C. Hastings, Grace C. Hsu, Michael R. Jirousek,
Bernard D. Johnson, Suresh S. Kerwar, Steven R.
Schow, Allan Wissner, Nan Zhang, and Michael M. Wick.
Bioorg. & Med. Chem. Lett. 1993,
3, 1595-600.
Determination of the
Loading Values for High Levels of Drugs and Sugars
Conjugated to Proteins by Matrix-Assisted Ultraviolet
Laser Desorption/Ionization Mass Spectrometry.
Siegel, M.M.; Tsou, H.; Lin, B.; Hollander, I.J.;
Wissner, A.; Karas, M.; Ingendoh, A.; Hillenkamp, F.
Biol. Mass Spect.,1993, I,
369-376.
Effect of A Series of
1-Alkyl Ether Lipids on Inhibition of Phospholipase
A2 Activity and PAF Responses. Kohler, C.; Carroll,
M.; Tarrant, E.; Torley, L.; Wissner, A.
Inflammation, 1993, 17(3),
245-261.
Analogues of Platelet
Activating Factor. 8. Antagonists of PAF Containing
an Aromatic Ring Linked to A Pyridinium Ring. Trova,
M.P.; Wissner, A.; Carroll, M.; Kerwar, S.S.;
Pickett, W.C.; Schaub, R.E.; Torley, L.W.; Kohler,
C.A. J. Med. Chem. 1993,
36, 580.
Analogues of Platelet
Activating Factor. 7. Bis-Aryl Amide and Bis-Aryl
Urea Receptor Antagonists of PAF. Wissner, A.;
Carroll, M.; Johnson, B.D.; Kerwar, S.S.; Pickett,
W.C.; Schaub, R. E.; Torley, L.W.; Trova, M.P.;
Kohler, C.A. J. Med. Chem., 1992,
35(26), 4779-4789.
Disodium
(R,R)-5-{2-{{2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate
(CL 316,243). A Potent ß-Adrenergic Agonist Virtually
Specific for ß3 Receptors. A Promising Antidiabetic
and Antiobesity Agent. Bloom, Jonathan D.; Dutia,
Minu D.; Johnson, Bernard D.; Wissner, Allan; Burns,
Michael G.; Largis, Elwood E.; Dolan, Jo Alene;
Claus, Thomas H. J. Med. Chem.,
1992, 35(16),
3081-3084.
Studies of the Effect
of A Platelet-Activating Factor Antagonist, CL
184005, in Animal Models of Gram-Negative Bacterial
Sepsis. Torley, L.W.; Pickett, W.C.; Carroll, M.L.;
Kohler, C.A.; Schaub, R.E.; Wissner, A.; DeJoy, S.Q.;
Green, K.E.; Oronsky, A.L.; Kerwar, S.S.
Antimicrobial Agents and Chemotherapy,
1992, 36(9),
1971-1977.
Analogues of Platelet
Activating Factor. 6. Mono and Bis-Aryl Phosphate
Antagonists of PAF. Wissner, A.; Carroll, M.L.;
Green, K.E.; Kerwar, S.S.; Pickett, W.C.; Schaub,
R.E.; Torley, L.W.; Wrenn, S.; Kohler, C.A. J. Med.
Chem., 1992, 35(9),
1650-1662.
QS-Edit 1.0: A Query
Structure Editor for the Macintosh for Use with the
CAS Online Registry and Beilstein Databases. Wissner,
A. Tetrahedron Comput. Method.,
1990, 3(2), 73-82.
HMO version 1.1: A
Huckel Molecular Orbital Program for the Macintosh.
Wissner, A. Tetrahedron Comput. Method.,
1990, 3(2), 63-71.
The Efficient Synthesis
of Two Prostaglandin Intermediates. Hamann, P.R.;
Wissner, A. Syn. Comm. 1989,
19(9&10), 1509-1518
Analogs of Platelet
Activating Factor. 5. Multiple Oxygen Substitution of
the Alkoxy Chain. Wissner, A.; Kohler, C.A.;
Goldstein, B.M. J. Med. Chem., 1986,
29(7), 1315-19.
Analogs of Platelet
Activating Factor. 4. Some Modifications of the
Phosphocholine Moiety. Wissner, A.; Schaub, R.E.;
Sum, P.E.; Kohler, C.A.; Goldstein, B.M. J. Med.
Chem., 1986, 29(3),
328-33
Imidazo[1,5-d][1,2,4]triazines as
Potential Antiasthma Agents. Paul, R.; Brockman,
J.A.; Hallett, W.A.; Tarrant, M.; Torley, L.W.;
Callahan, F.M.; Fabio, P.F.; Lenhard, R.H.; Schaub,
R.E.; Wissner, A. J. Med. Chem.,
1985, 28(11),
1704-16
Analogs of Platelet
Activating Factor. 3. Replacement of the Phosphate
Moiety with A Sulfonylbismethylene Group. Wissner,
Allan; Kohler, C.A.; Goldstein, B.M. J. Med. Chem.,
28(9), 1365-7, 1985
Analogs of Platelet
Activating Factor (PAF). 2. Some Modifications of the
Glycerine Backbone. Wissner, A.; Schaub, R.E.; Sum,
P.E.; Kohler, C.A.; Goldstein, B.M. Med. Res. Div.,
American Cyanamid Co. J. Med. Chem.,
1985, 28(9), 1181-7
Analogs of Platelet
Activating Factor (PAF). 1. Some Modifications of the
Alkoxy Chain. Wissner, A.; Sum, P.E.; Schaub, R.E.;
Kohler, C.A.; Goldstein, B.M. J. Med. Chem.,
1984, 27(9),
1174-81.
Hypotensive and
Vasodilatory Activity of
(.+-.)-1-O-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine
in the Normotensive Rat. Lai, F.M.; Shepherd, C.A.;
Cervoni, P.; Wissner, A. Life Sci.,
1983, 32(10),
1159-66.
Prostaglandins and
Congeners. 25. Inhibition of Gastric Acid Secretion.
Replacement of the Carboxylate Moiety of a
Prostaglandin with a Hydroxymethylketo Functional
Group. Wissner, Allan; Birnbaum, Jay E.; Wilson,
Donald E. J. Med. Chem., 1980,
23(7), 715-17.
Prospects for a
Prostaglandin Bronchodilator. Grudzinskas, Charles
V.; Skotnicki, Jerauld S.; Chen, Sow-Mei L.; Floyd,
M. Brawner, Jr.; Hallett, William A.; Schaub, Robert
E.; Siuta, Gerald J.; Wissner, Allan; Weiss, Martin
J.; Dessy, Franz. ACS Symp. Ser., Volume Date 1978,
118(Drugs Affecting Respir. Syst.),
1980, 301-77.
2-Heterosubstituted
Silylated Ketone Acetals: Reagents for the
Preparation of .alpha.-Functionalized Methylketones
from Carboxylic Acid Chlorides. Wissner, Allan. J.
Org. Chem., 1979, 44(25),
4617-22.
15-Deoxy-16-hydroxyprostaglandins
Synthesis and Bronchodilator Activity. Grudzinskas,
C.V.; Chen, S.M.L.; Floyd, M.B.; Lenhard, R H.;
Schaub, R.E.; Siuta, G. J.; Weiss, M. J.; Wissner,
A.; Dessy, F.; Van Humbeeck, L. Chem., Biochem.,
Pharmacol. Act. Prostanoids, Incl. Proc. Symp.,
Meeting Date 1978, 243-57. Edited by: Roberts,
Stanley M.; Scheinmann, Feodor. Pergamon: Oxford,
Engl., 1979
Tris[trimethylsilyloxy]ethene: A
Convenient Preparation of 2,3-dihydroxyalkanoic Acids
from Aldehydes. Wissner, A. Synthesis,
1979, 1, 27-8,
Tris(trimethylsilyloxy)ethylene:
The Conversion of Carboxylic Acid Chlorides to
Hydroxymethylketones. Wissner, A. Tetrahedron Lett.,
1978, 31, 2749-52.
Reaction of
tert-butyldimethylsilyl Esters with Oxalyl
Chloride-dimethylformamide: Preparation of Carboxylic
Acid Chlorides Under Neutral Conditions. Wissner,
Allan; Grudzinskas, Charles V. J. Org. Chem.,
1978, 43(20), 3972-4
Prostaglandins and
Congeners XIII (1). The Synthesis of
DL-erythro-16-methoxyprostaglandins. Hallett, W.A.;
Wissner, A.; Grudzinskas, C.V.; Partridge, R.;
Birnbaum, J.E.; Weiss, M.J. Prostaglandins,
1977, 13(3),
409-15.
Prostaglandins and
Congeners. XII. The Synthesis of dl-erythro and
dl-threo-15,16-dihydroxyprostaglandins. Hallett,
W.A.; Wissner, A.; Grudzinskas, C.V.; Weiss, M.J.
Chem. Lett., 1977, 1,
51-4.
Prostaglandins and
Congeners. 11. Synthesis of dl-13-hydroxyprostanoic
Acids. Wissner, A. J. Org.
Chem.,1977, 42(2),
356-8,.
Synthesis of
Tricarbonyliron Complexes of Functional
1,2-disubstituted Cyclobutadienes. Berens, George;
Kaplan, Fred; Rimerman, Ronald; Roberts, Bryan W.;
Wissner, Allan J. Am. Chem. Soc.,
1975, 97(24),
7076-85.
Anti-Tricyclo[3.1.2,4]hexanes.
Synthesis and Reactions. Wissner, Allan; Meinwald,
Jerrold J. Org. Chem., 1973,
38(9), 1697-702.
Generation of
Dimethylenecyclobutenes from Cyclobutadieneiron
Tricarbonyl Complexes. Synthesis of
Cyclobutadienopleiadiene and
.alpha.,.alpha.,-diphenyldimethylenecyclobutene.
Roberts, Bryan W.; Wissner, Allan. J. Amer. Chem.
Soc., 1972, 94(20),
7168-9.
Evidence on the Scope
and Limitations of Ring-forming Reactions of
Tricarbonyliron Complexes of Functional
1,2-disubstituted Cyclobutadienes. Synthesis of
Tricarbonyliron Complexes of
Cyclobutadienocycloheptatrienyl Derivatives. Roberts,
Bryan Wilson; Wissner, Allan J. Amer. Chem. Soc.,
1970, 92(21),
6382-4.
Tricarbonyliron
Complexes of Functional 1,2-disubstituted
Cyclobutadienes. Roberts, Bryan Wilson; Wissner,
Allan; Rimerman, Ronald A. J. Amer. Chem. Soc.,
1969, 91(22),
6208-9.
Meeting
Presentations/ Posters
4-Heteroarylamino-5-phenyl-3-pyridinecarbonitriles
as PKC-Theta Inhibitors T. Nittoli; C. Ingalls; R. G.
Dushin; A. Wissner,;D. H. Boschelli; J. Lee; X. Yang;
P. Morgan; A. Brennan; D. Chaudhary,31st NatioNal
Medicinal Chemistry Symposium, University of
Pittsburgh, Abstract number 105, June 15-19,
2008.
Quinazoline-based
Quinones as Irreversible KDR Inhibitors: Attenuating
the Reactivity of the Quinone by Varying the
Substituents on the Quinone Ring. Thomas Nittoli,
Heidi Fraser, Charles L. Ingalls, Bernard D. Johnson,
Russell G. Dushin§, M. Brawner Floyd, Katherine
Cheung, Joseph Marini, Malini R. Ravi, Xingzhi Tan,
Sylvia Musto, Frank Loganzo, Allan Wissner. Gordon
Research Conference-Heterocyclic Chemistry, Newport
RI USA (Salve Regina University), July 2-7,
2006
Dual Irreversible
Kinase Inhibitors: Incorporation of Two
Thiol-reactive Centers that Independently Target
Specific, Nonconserved, Cysteine Residues In Egfr And
Vegfr-2. Russell G. Dushin*, Katherine Cheung, M.
Brawner Floyd, Heidi L. Fraser, Charles L. Ingalls,
Thomas Nittoli, Allan Wissner, Malini R. Ravi,
Xingzhi Tan, and Frank Loganzo. 2006 NJACS Organic
Topical Group Award Symposium For Creativity in
Molecular Design and Synthesis, ,Sommerset, NJ,
September 20, 2006
Dual Irreversible
Kinase Inhibitors: Incorporation of Two Reactive
Centers Each Independently Targeting Specific,
Nonconserved, Cysteine Residues In Egfr And Vegfr-2.
Heidi L. Fraser, Charles L. Ingalls, Russell G.
Dushin, M. Brawner Floyd, Katherine Cheung, Thomas
Nittoli, Malini R. Ravi, Xingzhi Tan, Frank Loganzo,
and Allan Wissner, 30th National Medicinal Chemistry
Symposium Seattle WA., June 25-29,
2006.
Analysis of Covalent
Reactions of KDR Protein with Substituted Quinazoline
Quinones by Electrospray- and MALDI-Mass
Spectrometry. Marshall M Siegel; Frank Loganzo; Allan
Wissner; Heidi Fraser; Bernard Johnson; Russell
Dushin; Malini Ravi, Proceedings of the 53rd American
Society of Mass Spectrometry Conference on Mass
Spectrometry & Allied Topics, San Antonio, TX. ,
Poster TP28,June 5-9, 2005.
Irreversible binding
inhibitors of KDR kinase inhibit receptor
autophosphorylation in cells, endothelial cell
proliferation, and tumor growth in vivo. Frank
Loganzo Jr., Xingzhi Tan, Sylvia Musto, Tami Annable,
Carolyn Discafani, Jon Golas, Janet Gruzas, Marshall
Siegel, Girija Krishnamurthy, WeiDong Ding, Ramaswamy
Nilakantan, Malini Ravi, Katherine Cheung, Brawner
Floyd, Charles Ingalls, Bernard Johnson, Tom Nittoli,
Russell Dushin, Heidi Fraser, Lee Greenberger, Allan
Wissner. Proc. Amer Assoc. Cancer Res.
2005; 46: 5829
Quinone-based
irreversible inhibitors of KDR kinase as potential
anti-angiogentic agents. Thomas Nittoli, Heidi
Fraser, Charles L. Ingalls, Bernard D. Johnson,
Russell D. Dushin, M. Brawner Floyd, Katherine
Cheung, Joseph Marini, Malini R. Ravi, Ramaswamy
Nilakantan, Xingzhi Tan, Sylvia Musto, Frank Loganzo,
Allan Wissner. Proc. Amer Assoc. Cancer Res.
2005; 46: 5826
EKB-569 and Cpd-820:
irreversible inhibitors of EGF-R and HER-2 kinase for
cancer therapy. Greenberger LM; Rabindran S; Wissner
A; Tsou HR; Zacharchuk C; Boni J Growth Factor
Receptors in Drugs Discovery & Development,
Philadelphia, PA, May 5-6,
2003
New substituted
4-anilinoquinoline-3-carbonitriles as potent, orally
active, irreversible inhibitors of the Her-2 receptor
tyrosine kinase for the treatment of cancers. Hwei-Ru
Tsou, Allan Wissner, Elsebe Overbeek, William A.
Hallett, Marvin F. Reich, M. Brawner Floyd, Bernard
D. Johnson, Ramaswamy Nilakantan, Ru Shen, Carolyn
M.Discafani, Edward C. Rosfjord, Yu-Fen Wang, and
Sridhar K. Rabindran. Chemical Sciences and Oncology
Research, Wyeth Research, Pearl River, NY. the 94th
AACR meeting, Washington, D.C., July 14,
2003
Synthesis and
evaluation of 4-anilino substituted
3-quinolinecarbonitriles as inhibitors of kinases of
the Ras-MAPK signaling cascade. Dan Berger, Minu
Dutia, Dennis Powell, Nancy Torres, Biqi Wu, Allan
Wissner, Nan Zhang, Jeremy Levin, Xuemei Du, Robert
Mallon, Donald Wojciechowicz, Connie Kohler. 224th
ACS National Meeting, Boston, MA, MEDI 105, August
18, 2002
Design and synthesis of
6,7- substituted 4-anilino-3-quinolinecarbonitriles
as potent inhibitors of kinases of the Ras-MAPK
signaling cascade. Minu Dutia, Dan Berger, Dennis
Powell, Nancy Torres, Biqi Wu, Erik Honores, Nan
Zhang, Jeremy Levin, Xuemei Du, M. Brawner Floyd,
Allan Wissner, Diane Boschelli, Robert Mallon, Donald
Wojciechowicz, Connie Kohler, 224th ACS National
Meeting, Boston, MA, MEDI 104, August 18,
2002
Antitumor activity of
compound 820: an orally active irreversible inhibitor
of the Her-2 receptor tyrosine kinase. Rabindran SK,
Discafani C, Rosfjord E, Shen R, Shi S, Wang YF, Tsou
HR, Hallet W, Johnson B, Floyd B, Wissner A. 93rd
American Association of Cancer Research, San
Francisco, Apr 6-10, 2002. Proceedings of the
American Association for Cancer Research
43:1001-1002, Abstr: 4965, 2002
Mar
Synthesis and
structure-activity relationships of
3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK)
inhibitors. Zhang, Nan; Wu, Biqi; Powell, Dennis W.;
Wissner, Allan; Floyd, Middleton B.; Kovacs, Eleonora
D.; Toral-Barza, Lourdes; Kohler, Constance. Abstr.
Pap. - Am. Chem. Soc. 2001, 221st
MEDI-142.
Synthesis and
structure-activity relationships for soluble
6-substituted 4-anilinoquinoline-3-carbonitriles.
Orally active, irreversible inhibitors of the
tyrosine kinase activity of the epidermal growth
factor receptor (EGFR). Tsou HR; Overbeek E; Reich
MF; Floyd MB; Johnson BD; Gruber BC; Ye F; Hallett
WA; Nilakantan R; Shen R; Wang YF; Greenberger LM;
Wissner A 2nd International Conference on Inhibitors
of Protein Kinases and the Workshop on Molecular
Modelling Methods, Warsaw, Poland, Sep 9-15,
2001
The use of irreversible
inhibitors of epidermal growth factor receptor
tyrosine kinase in the treatment of tumors, colonic
polyps, and polycystic kidney disease. Greenberger
LM; Discafani C; Nunes M; Tsou HR; Nilakantan R;
Frost P; Wissner A . Protein Kinases in Drug
Discovery & Development, Princeton, NJ, Oct
15-16, 2001
Inhibition of Src
Kinase Activity by a Series of
4-Anilino-3-cyanoquinolines F.Ye, D. H. Boschelli, Y.
D, Wang, B. Wu, N. Zhang, M. Dutia, D. W. Powell, A.
Wissner, F. Boschelli. Abstracts of Papers American
Chemical Society 220(Part 1):MEDI 52, 2000 220th
National Meeting of the American Chemical Society,
Washington DC, Washington DC, USA, August20-24,
2000
EKB-569: a new
irreversible inhibitor of epidermal growth factor
receptor tyrosine kinase for the treatment of cancer.
LM Greenberger, C Discafani, YF Wang, HR Tsou, EG
Overbeek, R Nilakantan, P Frost, A Wissner. 11th
NCI-EORTC-AACR Symposium on New Drugs in Cancer
Therapy, Nov. 7-10, 2000, Vrije
Universiteit, Amsterdam, The Netherlands, Abstract
388.
EKB-569: a new
irreversible inhibitor of epidermal growth factor
receptor tyrosine kinase for the treatment of cancer.
LM Greenberger, C Discafani, YF Wang, M Nunes., HR
Tsou, EG Overbeek, R Nilakantan, P Frost, A Wissner.
Clinical Cancer Research 6, Suppl. 4544S,
2000.
Inhibition of epidermal
growth factor receptor tyrosine kinase family members
of the covalent antagonists CL-387,785. Discafani CM;
Floyd MB; Johnson BD; Nilakantan R; Nunes M; Shen R;
Wang YF; Wissner A; Greenberger LM Proceedings
American Association for Cancer Research Annual
Meeting pp. 729-730, 1999, Mar 90th Annual Meeting of
the American Association for Cancer Research,
Philadelphia, Pennsylvania, USA, April 10-14,
1999
Effects of CL 184005, a
PAF Receptor Antagonist on Vascular Reactivity and
Blood Pressure. Torley, L.W.; Kohler, C.A.; Shepherd,
C.; Lai, F.; Wissner, A. Pharmacologist, 35(3), 197,
1993; ASPET 1993, San Francisco, CA, July 30-Aug 3,
1993, Abstract No. 361
Efficacy of a New PAF
Antagonist, CL 184005 in Models of Endotoxemia.
Pickett, W.C.; Torley, L.W.; Kohler, C.A.; Wissner,
A.; Trova, M.; Kerwar, S.S. Fourth International
Congress on PAF and Related Lipid Mediators,
Snowbird, UT, Sept. 22-25, 1992,
Abstract No. PO1.30.
Evaluation of
Combination Therapy in Murine Endotoxemia: Studies
with Monoclonal Anti-LPS and CL 184005, a PAF
Antagonist. Torley, L.W.; DeJoy, S.Q.; Jeyaseelan,
R.; Wissner, A.; Kerwar, S.S. Second Conference on
the International Endotoxin Society, Vienna, Austria,
Aug. 17-20, 1992, Abstract No.
289.
CL 184005, A Potent PAF
Antagonist Prevents LPS Induced Morbidity and
Mortality in Rodents, Rabbits, and Monkeys. Torley,
L.W.; Kohler, C.A.; Pickett, W.C.; Wissner, A.;
Kerwar, S.S. Second Conference on the International
Endotoxin Society, Vienna, Austria, Aug. 17-20,
1992, Abstract No. 288.
Aryl Amide, Imide, and
Carbamate Pyridinium Antagonists of Platelet
Activating Factor (PAF). Trova, M.P.; Wissner, A.;
Carroll, M.; Kerwar, S.S.; Pickett, W.C.; Schaub,
R.E.; Torley, L.W.; Kohler, C.A. Gordon Research
Conference on Natural Products, New Hampton, NH, July
20-24, 1992.
Unusual Ortho Effect in
the Fast Atom Bombardment Mass Spectra of Platelet
Activating Factor Antagonists Containing Bis-Aryl
Phosphate Moieties. Siegel, M.M.; Tsao, R.; Wissner,
A. The 40th ASMS Conference on Mass Spectrometry and
Allied Topics Washington DC, June 1-5,
1992.
Structure Activity
Relationships in a Series of Aryl Phosphate PAF
Antagonists. Kohler, C.; Carroll, M.; Green, K.;
Kerwar, S.; Pickett, W.; Schaub, R.; Tarrant, E.;
Torley, L.; Wrenn, S.; Wissner, A. XI International
Congress of Pharmacology IUPHAR Satellite Meeting
Advances in Platelet-Activating Factor Research,
Institut Pasteur, Paris, June 28-29, 1990. Abstract
published in: J. Lipid Mediators, 2(3 + 4), 210,
1990.
Some Analogs of
Platelet Activating Factor Containing Modifications
of the Phosphocholine Moiety. Wissner, A.; Schaub,
R.E.; Sum, P.E.; Kohler, C.A.; Goldstein, B.M.
Symposium on New Horizons in Platelet Activating
Factor Research, Hilton Head, South Carolina,
Abstract No. 37, 1985.
Effect of a PAF Analog
on Phospholipase Activity and PAF Responses. Kohler,
C.A.; Tarrant, E.; Torley, L.; Vaughn, G.; Wissner,
A.; Wrenn, S. Conference on "There is a Case for
PAF-Acether Antagonists", Institut Pasteur, Paris,
France. Abstract published in: Prostaglandins,35(5),
843, 1988.
U.S.
Patents
Substituted
3-Cyanoquinolines. Wissner, Allan; Hwei-Ru, Tsou;
Berger, Dan M.; Floyd, Middleton B.; Hamann R.,
Philip; Zhang, Nan.; Frost, Philip. , U.S. RE42376 E,
17 May 2011
Protein tyrosine kinase
enzyme inhibitors. Wissner, Allan; Rabindran, Sridhar
Krishna; Tsou, Hwei-Ru, US7982043, 2011
Substituted
3-cyanopyridines as protein kinase inhibitors. Cole;
Derek Cecil, Boschelli; Diane Harris, Wang; Yanong
Daniel, Asselin; Magda, Joseph-McCarthy; Diane Marie,
Prashad; Amarnauth Shastrie, Wissner; Allan, Dushin;
Russell , Wu; Biqi , Tumey; Lawrence Nathan, Niu;
Chuan S., Chen; Joan, US 7781591, Aug. 24,
2010
Substituted
3-cyanopyridines as protein kinase inhibitors. Cole,
Derek Cecil; Boschelli, Diane Harris; Wang, Yanong
Daniel; Asselin, Magda; Joseph-Mccarthy, Diane Marie;
Prashad, Amarnauth Shastrie; Wissner, Allan; Dushin,
Russell; Wu, Biqi; Tumey, Lawrence Nathan; Niu, Chuan
S.; Chen, Joan. U.S. Pat. Appl. Publ, 2007, US
2007287708 A1
Preparation of
cyanopyridines as protein kinase inhibitors. Cole,
Derek Cecil; Asselin, Magda; Boschelli, Diane Harris;
Wissner, Allan; Wang, Yanong Daniel; Prashad,
Amarnauth Shastrie; Dushin, Russell.U.S. Pat. Appl.
Publ., 2007 US 2007287738 A1
Tricyclic Protein
Kinase Inhibitors. Berger, Dan M.; Dutia, Minu D.;
Demorin, Frenel F.; Boschelli, Diane H.; Powell,
Dennis W.; Tsou, Hwei-ru; Wissner, Allan; Zhang, Nan;
Ye, Fei; Wu, Biq U.S. 7105531, Sep. 12, 2006
A preparation of
cyanoquinoline derivatives, useful as protein
tyrosine kinase enzyme inhibitors (antitumor agents).
Wissner, Allan; Rabindran, Sridhar Krishna; Tsou,
Hwei-Ru. U.S. Pat. Appl. Publ. (2005),
2005059678 A1
3-Cyanoquinolines as
Inhibitors of EGFR and HER2 Kinases. Wissner, Allan;
Hwei-Ru, Tsou; M.; Floyd, Middleton B.; Bernard D.
Johnson; Overbeek-Klumpers, Elsebe. US 6821988, Nov.
23, 2004
3-Cyanoquinolines,
3-cyano-1,6-napthyridines, and
3-cyano-1,7-napthyridines as protein kinase
inhibitors. Boschelli, Wang, Yanong; Boschelli, Frank
Charles; Berger, Dan Maarten; Zhang, Nan; Powell,
Dennis William; Ye, Fei; Yamashita, Ayako; Demorin,
Frenel Fils; Wu, Biqi; Tsou, Hwei-ru;
Overbeek-Klumpers, Elsebe Geraldine; Wissner, Allan.
US 6689772, Feb. 10, 2004
Tricyclic Protein
Kinase Inhibitors. Berger, Dan; Dutia, Minu;Frenel,
DeMorin, Boschelli, Diane; Powel, Dennis; Tsou,
Hwei-Ru; Wissner, Allan: Zhang, Nan; Fei, Ye;Biqi,
Wu. US 6638929, Oct. 28, 2003
Tricyclic Protein
Kinase Inhibitors. Tsou, Hwei-Ru; Overbeek-Klumpers,
Elsebe Geraldine; Wissner, Allan. US 6608048, Aug.
19, 2003.
Preparation of aromatic
tricyclic compounds containing quinolinonitrile rings
as protein kinase inhibitors. Tsou, Hwei-Ru;
Overbeek-Klumpers, Elsebe Geraldine; Wissner, Allan.
US 2003065180, 2003.
Substituted
3-Cyano-[1.7],[1.5], and [1.8] Napphthyridine
Inhibitors of Tyrosine Kinases. Wissner, Allan;
Hamann, R. Philip; Yamashita, Ayko. American Cyanamid
Co., US 6548496, Apr. 15, 2003.
Substituted
3-Cyano-[1.7],[1.5], and [1.8] Napphthyridine
Inhibitors of Tyrosine Kinases. Wissner, Allan;
Hamann, R. Philip; Yamashita, Ayko. American Home
Products Co.., U.S. 6355636 March 12, 2002.
3-Cyanoquinolines,
3-cyano-1,6-naphthyridines, and
3-cyano-1,7-naphthyridines as protein kinase
inhibitors. Boschelli, Diane Harris; Wang, Yanong;
Boschelli, Frank Charles; Berger, Dan Maarten; Zhang,
Nan; Powell, Dennis William; Ye, Fei; Yamashita,
Ayako; Demorin, Frenel Fils; Wu, Biqi; Tsou, Hwei-ru;
Overbeek-Klumpers, Elsebe Geraldine; Wissner, Allan
US 2002026052 , 2002.
Tricyclic Protein
Kinase Inhibitors. Berger, Dan M.; Dutia, Minu D.,
DeMorin, Frenel F., Boschelli, Diane H., Powell,
Dennis, W., Hwei-Ru, Wissner, Allan Tsou; Zhang, Nan,
Ye, Fei; Wu, Biqi. American Home Products Co.., U.S.
20010051620 Dec. 13, 2001.
Substituted
3-Cyanoquinolines. Wissner, Allan; Hwei-Ru, Tsou;
Berger, Dan M.; Floyd, Middleton B.; Hamann R.,
Philip; Zhang, Nan.; Frost, Philip. American Cyanamid
Co., U.S. 6297258, 2 Oct 2001
Substituted
3-Cyanoquinolines. Wissner, Allan; Hwei-Ru, Tsou;
Berger, Dan M.; Floyd, Middleton B.; Hamann R.,
Philip; Zhang, Nan;Salvati, Mark E.; Frost, Philip.
American Cyanamid Co., U.S. 6288082, 11 Sept
2001
Substituted Quinazoline
Derivatives. Wissner, Allan; Hwei-Ru, Tsou; Johnson,
Bernard D; Hamann R., Philip; Zhang, Nan; American
Cyanamid Co., U.S. 6251912, 26 June 2001
Substituted 3-Cyano
Quinolines. Wissner, Allan; Johnson, Bernard D;
Reich, Marvin, F; Floyd, Middleton B.; Kitchen,
Douglas B.; Hwei-Ru Tsou. American Cyanamid Co., U.S.
6002008, 14 Dec 1999
4-Aminoquinazoline EGFR
Inhibitors. Wissner, Allan; Johnson, Bernard
D.;Floyd, Middleton B.; Kitchen, Douglas B. American
Cyanamid Co., U.S. 5760041, 2 Jun 1998
Asymmetric Synthesis of
Intermediates for Retroviral Protease Inhibitor
Compounds. Wissner, Allan; Trova, M.P. American
Cyanamid Co., U.S. 5569762A, 29 Oct 1996.
Hydroxy-phosphinyl-oxy-phenyl-methyl-imidazolium
hydroxide Inner Salts as PAF Antagonists. Wissner,
Allan; Schaub, Robert E.; Sum, Phaik E. American
Cyanamid Co., U.S. 5411983A, 4 May 1995.
Bis-aryl amide and Urea
Antagonists of Platelet Activating Factor. Wissner,
Allan. American Cyanamid Co., U.S. 5432189A, 27 Jul
1995.
Retroviral Protease
Inhibitors. Michael P. Trova, Robert E. Babine, Nan
Zhang, Steven R. Schow, Allan Wissner. American
Cyanamid Co., U.S. 5430150A, 4 Jul 1995.
Asymmetric Synthesis of
Intermediates for Retroviral Protease Inhibitor
Compounds. Wissner, Allan; Trova, M.P. American
Cyanamid Co., U.S. 5428167A, 27 June 1995.
Bis-aryl Amide
Antagonists of Platelet Activating Factor. Wissner,
Allan. American Cyanamid Co., U.S. 5350759A, 27 Sept
1994.
Aryl Pyridinium
Compounds Which are Useful in Treating Shock. Michael
P. Trova; Wissner, Allan. American Cyanamid Co., U.S.
5328921A, 12 Jul 1994.
Bis-arylphosphate Ester
Antagonists of Platelet Activating Factor. Wissner,
Allan; Green, Kenneth; Schaub, Robert E. American
Cyanamid Co., U.S. 5328901A, 12 Jul 1994.
Phosphinyloxy-phenyl-methyl-pyridinium
hydroxide Inner Salts Useful as Antagonists of PAF.
Wissner, Allan; Schaub, Robert E.; Sum, Phaik E.
American Cyanamid Co., U.S. 5234918A, 4 Apr
1993.
Method of Making
Certain Aryl Containing Amides. Wissner, Allan.
American Cyanamid Co., U.S. 5231182A, 27 Jul
1993.
Bis-Aryl Amide and Urea
Antagonists of Platelet Activating Factor. Wissner,
Allan. American Cyanamid Co., U.S. 5225425A, 6 Jul
1993.
Certain
Hydroxy-phosphinyloxy-phenyl-methyl-thiazolium
hydroxide Salts as PAF Antagonists. Wissner, Allan;
Schaub, Robert E.; Sum, Phaik E. American Cyanamid
Co., U.S. 5215975A, 1 Jun 1993.
Pyridinium Compounds
Which are Useful as Antagonists of Platelet
Activating Factor. Trova, Michael; Wissner, Allan.
American Cyanamid Co., U.S. 5208247A, 4 May
1993
Phosphocholine
Derivative Inhibitors of Phospholipase A2. Wissner,
Allan; Schaub, Robert E. American Cyanamid Co., U.S.
5208223, 4 May 1992.
Method for the
Treatment of Endotoxic Shock in a Mammal. Wissner,
Allan; Kerwar, Suresh S.; Kohler, Constance. American
Cyanamid Co., U.S. 5176908A, 5 Jan 1993.
Phosphocholine
Derivative Inhibitors of Phospholipase A2. Wissner,
Allan; Schaub, Robert E.; Green, Kenneth; Hamann,
Philip, R. American Cyanamid Co., U.S. 5144045, 1
Sept 1992.
Bis-Aryl Amide and Urea
Antagonists of Platelet Activating Factor. Wissner,
Allan. American Cyanamid Co., U.S. 5128351A, 7 Jul
1992.
Bis-arylphosphate Ester
Antagonists of Platelet Activating Factor. Wissner,
Allan; Green, Kenneth; Schaub, Robert E. American
Cyanamid Co., U.S. 5147864A, 15 Sept 1992.
Sulfur Inhibitors of
Phospholipase A2. Wissner, Allan. American Cyanamid
Co., U.S. 5126291A, 30 Jun 1992.
Method for the
Treatment of Endotoxic Shock in a Mammal. Wissner,
Allan; Kerwar, Suresh S.; Kohler, Constance. American
Cyanamid Co., U.S. 5124147A, 23 Jun 1992.
Antihypertensive
Phosphate Derivatives and Intermediates Thereof.
Wissner, Allan; Schaub, Robert E.; Sum, Phaik E.
American Cyanamid Co., U.S. 4981989A, 1 Jan
1991.
Method of Preparing
Bis-Aryl Amide and Urea Antagonists of Platelet
Activating Factor. Wissner, Allan. American Cyanamid
Co., U.S. 5077409A, 31 Dec 1991.
Bis-arylphosphate Ester
Antagonists of Platelet Activating Factor. Wissner,
Allan; Green, Kenneth; Schaub, Robert E. American
Cyanamid Co., U.S. 4983592A, 8 Jan 1991.
Antihypertensive
Phosphate Derivatives. Wissner, Allan. American
Cyanamid Co., U.S. 4939127A, 3 Jul 1990.
Antihypertensive
Derivatives. Wissner, Allan; Schaub, Robert E.
American Cyanamid Co., U.S. 4900731A, 13 Feb
1990.
Antihypertensive
Derivatives. Wissner, Allan; Sum, Phaik E. American
Cyanamid Co., U.S. 4897385A, 30 Jan 1990.
Antihypertensive
Derivatives. Wissner, Allan; Schaub, Robert E.; Sum,
Phaik E. American Cyanamid Co., U.S. 4894367A, 16 Jan
1990.
Antihypertensive
Derivatives. Wissner, Allan; Schaub, Robert E.; Sum,
Phaik E. American Cyanamid Co., U.S. 4883816A, 28 Nov
1989.
Antihypertensive
Phosphate Derivatives. Wissner, Allan; Schaub, Robert
E. American Cyanamid Co., U.S. 4827011A, 2 May
1989.
Precursors and
synthesis of
methyl-9-oxo-11a,16-dihydroxy-16-vinyl-5-cis-13-trans-prostadienoates.
Wissner, Allan; Green, Kenneth E.; Hamann, Philip R.;
Levin, Jeremy. American Cyanamid Co., U.S. 4762935A,
9 Aug 1988.
Antihypertensive
Phosphate Derivatives. Wissner, Allan; Schaub, Robert
E.; Sum, Phaik E. American Cyanamid Co., U.S. 4762942
A, 9 Aug 1987.
Antihypertensive
Phosphate Derivatives. Wissner, Allan; Schaub, Robert
E.; Sum, Phaik E. American Cyanamid Co., U.S. 4703130
A, 27 Oct 1987.
Antihypertensive
Phosphate Derivatives. Wissner, Allan; Schaub, Robert
E.; Sum, Phaik E. American Cyanamid Co., U.S.
4697031A, 29 Sept 1987.
Antihypertensive
Phosphate Derivatives. Wissner, Allan; Schaub, Robert
E.; Sum, Phaik E. American Cyanamid Co., U.S.
4699990A, 13 Oct 1987.
Phosphocholine
derivatives having antihypertensive action. Wissner,
Allan; Schaub, Robert E.; Sum, Phaik E. American
Cyanamid Co., U.S. 4640913A, 3 Feb 1987.
16-Hydroxy-5-iodoprostacyclin
analogs of the 1 series. Grudzinskas, Charles V.;
Chen, Sow Mei Lai; Wissner, Allan. American Cyanamid
Co., U.S. 4390711A, 28 Jun 1983.
Prostacyclin analogs
and related analogs. Grudzinskas, Charles Vincent;
Chen, Sow Mai Lai; Wissner, Allan. American Cyanamid
Co., Eur. Pat. Appl. EP 52204 A1, 26 May 1982.
1-Hydroxymethyl-11-deoxy-16-hydroxyprosten-1-ol
derivatives. Wissner, Allan; Floyd, Middleton B., Jr.
American Cyanamid Co., U.S. 4310700A, 12 Jan
1982.
1-Hydroxymethyl-1-oxo-prostane
derivatives of the E series. Wissner, Allan. American
Cyanamid Co., U.S. 4299988A, 10 Nov 1981.
1-Hydroxymethyl-11,16-dihydroxy-prosten-1-ol
derivatives. Wissner, Allan; Floyd, Middleton B., Jr.
American Cyanamid Co., U.S. 4288632A, 8 Sept
1981.
1-Hydroxymethyl-11,15-dihydroxy-prosten-1-ol-derivatives.
Wissner, Allan; Floyd, Middleton B., Jr. American
Cyanamid Co., U.S. 4288630A, 8 Sept 1981.
1-Hydroxymethyl-11-deoxy-16-hydroxy-prosten-1-ol-derivatives.
Wissner, Allan; Floyd, Middleton B., Jr. American
Cyanamid Co., U.S. 4288633A, 8 Sept 1981.
1-Hydroxmethyl-11-deoxy-15-hydroxyprosten-1-ol
derivatives. Wissner, Allan; Floyd, Middleton B., Jr.
American Cyanamid Co., U.S. 4291175A, 22 Sept
1981.
1-Hydroxymethylprosten-1-ol
derivatives. Wissner, Allan; Floyd, Middleton B., Jr.
American Cyanamid Co., U.S. 4289910A, 15 Sept
1981.
1-Hydroxymethyl-11-deoxy-15-hydroxy-prosten-1-ol-derivatives.
Wissner, Allan; Floyd, Middleton B., Jr. American
Cyanamid Co., U.S. 4288629A, 8 Sept 1981.
15-Deoxy-16-substituted-19-chloro-20-nor
prostane derivatives of the E and F series. Wissner,
Allan. American Cyanamid Co., U.S. 4278806, 14 Jul
1981.
Prostacyclin analogs of
the I series and related analogs. Grudzinskas,
Charles V.; Wissner, Allan; Chen, Sow-Mei L. American
Cyanamid Co., U.S. 4265904, 5 May 1981.
1-Hydroxymethyl-1-1-oxoprostane
derivatives of the E and F series. Wissner, Allan.
American Cyanamid Co., U.S. 4254285, 3 Mar
1981.
Prostacyclin analogs of
the I series and related analogs where the carboxylic
acid function has been replaced. Chen, Sow-Mei L.;
Grudzinskas, Charles V.; Wissner, Allan. American
Cyanamid Co., U.S. 4235924, 25 Nov 1980.
15-Deoxy-16-hydroxy-16-methyl-.DELTA.19-prostaglandins
of the E and F series. Wissner, Allan. American
Cyanamid Co., U.S. 4237307, 2 Dec 1980.
15-Deoxy-16-hydroxy-16-formyl or
dimethoxy-methyl-prostane derivatives of the E and F
series. Wissner, Allen; Grudzinskas, Charles V.
American Cyanamid Co., U.S. 4230879, 28 Oct
1980
15-Deoxy-16-hydroxy-17-methylene
prostaglandins of the E and F series. Wissner, Allan.
American Cyanamid Co., U.S. 4232166, 4 Nov
1980.
13-thiaprostaglandins.
Wissner, Allan. American Cyanamid Co., U.S. 4209639,
24 Jun 1980.
13-Hydroxy-15-deoxy-prostaglandins.
Wissner, Allan. American Cyanamid Co., U.S. 4039574,
2 Aug 1977
Look
here for links to these US and foreign patents